The DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.
TOP2A overexpression in hepatocellular carcinoma correlates with early age onset, shorter patients survival and chemoresistance
Open accessAbstract
Genomic gain represents an important mechanism in the activation of proto‐oncogenes. In many instances, induced oncogenes hold clinical implications both as prognostic markers and targets for therapeutic design. In hepatocellular carcinoma (HCC), although chromosomal gains are common, information on underlying oncogenes induced remains minimal. Here, we examined 7 causal sites of HCC for overexpressed genes by array‐based transcriptional mapping. In 22 HCC cell lines and early passages of cultures studied, clusters of up‐regulated genes were indicated, where TOP2A expression ranked the highest. Distinct TOP2A transcriptions were confirmed in an independent series of HCC tumors relative to adjacent non‐tumoral liver (p = 0.0018). By tissue microarray analysis of 172 HCC, we found TOP2A expressions correlated with advance histological grading (p < 0.001), microvascular invasion (p = 0.004) and an early age onset of the malignancy (≤40 years; p = 0.007). In conjunction with P‐gp and MRP1, TOP2A were further assessed for its association with chemotherapy responsiveness and survival in 148 patients who entered our recently reported Phase III prospective randomized study. In 73 chemoresistant and 75 nonresistant patients, only TOP2A positivity correlated with chemoresistance (p = 0.029) and shorter patients survival (p < 0.0001). The potential therapeutic value in targeting TOP2A by Etoposide, as a single agent, and in combination with Doxorubicin was also explored. In vitro cytotoxic studies suggested Etoposide at IC 20 readily reduced IC 50 values of Doxorubicin by a magnitude of ∼3.5 to 10‐fold compared to Doxorubicin alone (p < 0.028). Our study highlighted for the first time the prognostic value of TOP2A in HCC and the potential use of TOP2A reactive agents in therapy. © 2008 Wiley‐Liss, Inc.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Slamon, D. J., Leyland-Jones, B., Shak, S., Fuchs, H., Paton, V., Bajamonde, A., Fleming, T., Eiermann, W., Wolter, J., Pegram, M., et al. (2001) · New England Journal of Medicine · doi:10.1056/nejm200103153441101 · Cited by 11,500
Overexpression of a Transporter Gene in a Multidrug-Resistant Human Lung Cancer Cell Line
Cole, S. P. C., Bhardwaj, G., Gerlach, J. H., Mackie, J. E., Grant, C. E., Almquist, K. C., Stewart, A. J., Kurz, E. U., Duncan, A. M. V., & Deeley, R. G. (1992) · Science · doi:10.1126/science.1360704 · Cited by 3,037
Cited by
Resistance a major hindrance to chemotherapy in hepatocellular carcinoma: an insight
Lohitesh, K., Chowdhury, R., & Mukherjee, S. (2018) · Cancer Cell International · doi:10.1186/s12935-018-0538-7 · Cited by 270
Cellular Mechanisms of Liver Fibrosis
Acharya, P., Chouhan, K., Weiskirchen, S., & Weiskirchen, R. (2021) · Frontiers in Pharmacology · doi:10.3389/fphar.2021.671640 · Cited by 252
Metadata
- Authors
- Wong, N., Yeo, W., Wong, W., Wong, N. L. ‐., Chan, K. Y. ‐., Mo, F. K. ‐., Koh, J., Chan, S. L., Chan, A. T. ‐., Lai, P. B. ‐., Ching, A. K. ‐., Tong, J. H. ‐., Ng, H., Johnson, P. J., & To, K.
- Venue
- International Journal of Cancer
- Publisher
- Wiley
- Published
- 2008-11-11
- Volume
- 124
- Issue
- 3
- Pages
- 644-652
- ISSN
- 0020-7136 (ISSN-L)
- 1097-0215
- OpenAlex
- W2048793404
- Cited by
- 190
- References
- 2
- FWCI
- 5.72
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: TOP2A overexpression in hepatocellular carcinoma correlates with early age onset, shorter patients survival and chemoresistance. https://app.cochat.ai/papers/10.1002/ijc.23968
- The paper
- Wong, N., Yeo, W., Wong, W., Wong, N. L. ‐., Chan, K. Y. ‐., Mo, F. K. ‐., Koh, J., Chan, S. L., Chan, A. T. ‐., Lai, P. B. ‐., Ching, A. K. ‐., Tong, J. H. ‐., Ng, H., Johnson, P. J., & To, K. (2009). TOP2A overexpression in hepatocellular carcinoma correlates with early age onset, shorter patients survival and chemoresistance. International Journal of Cancer. https://doi.org/10.1002/ijc.23968
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.